Research Topics
| Ronald G HallSummaryAffiliation: Texas Tech University Health Sciences Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Multicenter evaluation of vancomycin dosing: emphasis on obesityRonald G Hall
Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas, USA
Am J Med 121:515-8. 2008..There is a paucity of data available regarding the dosing of antimicrobials in obesity. However, data are available demonstrating that vancomycin should be dosed on the basis of actual body weight...- Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort studyRonald G Hall
Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, TX, USA
BMC Pharmacol Toxicol 14:12. 2013..However, data are currently lacking regarding the effect of guideline-recommended weight-based dosing on nephrotoxicity in methicillin-resistant Staphylococcus aureus bacteremia (MRSAB)... - Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort studyRonald G Hall
Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, TX, USA
BMC Infect Dis 12:104. 2012..No studies have evaluated the effect of guideline-recommended weight-based dosing on in-hospital mortality of patients with methicillin-resistant Staphylococcus aureus bacteremia... - Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese peopleRonald G Hall
Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas, USA
Antimicrob Agents Chemother 56:1502-7. 2012..On the other hand, such reduced AUCs could lead to therapy failure. Thus, new and individualized ethambutol dosing regimens need to be designed for obese and extremely obese patients... - A formalized teaching, practice, and research partnership with the Veterans Affairs North Texas Health Care System: a model for advancing academic partnershipsRonald G Hall
Texas Tech University Health Sciences Center, TX, USA
Am J Pharm Educ 73:141. 2009..The VANTHCS/pharmacy school collaboration has clearly enhanced the ability of both institutions to exceed their teaching, research, and practice goals in a cost-effective manner... - Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases PharmacistsRonald G Hall
Department of Pharmacy Practice, Texas Tech University Health Sciences Center, Dallas, Texas 75235, USA
Pharmacotherapy 29:1468-81. 2009..These patient factors, the covariates for pharmacokinetic variability, and PK-PD factors suggest the need to individualize therapy for patients with tuberculosis in order to optimize outcomes and reduce the duration of therapy... 
Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatinAnthony J Busti
School of Pharmacy, Texas Tech University Health Sciences Center, Dallas, TX 75216, USA
J Cardiovasc Pharmacol 51:605-10. 2008..The objective is to study the pharmacokinetic interaction of RSV with atazanavir/ritonavir (ATV/RTV) or fosamprenavir/ritonavir (FPV/RTV)...- Empiric therapy for gram-negative pathogens in nosocomial and health care-associated pneumonia: starting with the end in mindAmy Arnold
Texas Tech University Health Sciences Center, Dallas, TX 75235, USA
J Intensive Care Med 25:259-70. 2010..Optimizing the use of current antimicrobials is paramount to ensure quality treatment options are available, given the lack of gram-negative antimicrobials in the pipeline... - Weight Drives Caspofungin Pharmacokinetic Variability in Overweight and Obese People: Fractal Power Signatures beyond Two-Thirds or Three-FourthsRonald G Hall
Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy
Antimicrob Agents Chemother 57:2259-64. 2013..This study protocol was registered at www.clinicaltrials.gov under registration number NCT01062165.)... - Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?Kathleen A Hazlewood
Texas Tech University Health Sciences Center, Dallas, TX, USA
Am J Med 123:182.e1-7. 2010..aureus isolates... 
Atazanavir for the treatment of human immunodeficiency virus infectionAnthony J Busti
Department of Pharmacy Practice, Texas Tech University Health Sciences Center School of Pharmacy, Dallas Ft Worth Regional Campus, Dallas, Texas, USA
Pharmacotherapy 24:1732-47. 2004..We conclude that atazanavir is a distinctively characteristic protease inhibitor owing to its in vitro potency, once-daily dosing, distinct initial resistance pattern, and infrequent association with metabolic abnormalities...- In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniaeDavid S Burgess
College of Pharmacy, University of Texas at Austin, Austin, TX, USA
Diagn Microbiol Infect Dis 49:41-6. 2004..pneumoniae, their activity against ESBL K. pneumoniae is limited and based on the size of the inoculum. Until more data are available, piperacillin/tazobactam and cefepime should not be used for the treatment of ESBL K. pneumoniae... - In vitro evaluation of the activity of two doses of Levofloxacin alone and in combination with other agents against Pseudomonas aeruginosaDavid S Burgess
College of Pharmacy, The University of Texas at Austin, Austin, TX, USA
Diagn Microbiol Infect Dis 46:131-7. 2003..aeruginosa may prove to be clinically beneficial and superior to combinations using lower doses of levofloxacin. In vivo studies are needed to evaluate the clinical significance of these findings... - Vancomycin dosing for methicillin-resistant staphylococcus aureus nosocomial pneumoniaRonald G Hall
Chest 132:1100-1; author reply 1102-3. 2007 - Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration dataDavid S Burgess
Center for Advancement of Research and Education in Infectious Diseases, College of Pharmacy, The University of Texas at Austin, Austin, Texas 78229, USA
Clin Ther 29:1421-7. 2007..Until the 2002 approval of levofloxacin 750 mg QD, ciprofloxacin was the fluoroquinolone of choice against Pseudomonas aeruginosa infections... - Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureusDarego O Maclayton
Texas Southern University College of Pharmacy and Health Sciences, Michael E DeBakey Veterans Affairs Medical Center, Houston, TX 77004, USA
Ann Pharmacother 41:235-44. 2007..To discuss current and potential treatment options for nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA)... - Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year periodDavid S Burgess
College of Pharmacy, University of Texas at Austin, USA
Pharmacotherapy 23:1232-7. 2003..To evaluate the microbiologic and clinical outcomes of patients with extended-spectrum beta-lactamase (ESBL)-producing isolates over a 2-year period...